Palmitoylethanolamide Induces Microglia Changes Associated with Increased Migration and Phagocytic Activity: Involvement of the CB2 Receptor

Overview

Journal Sci Rep

Specialty Science

Date 2017 Mar 25

PMID 28336953

Citations 70

Authors

F Guida

L Luongo

S Boccella

M E Giordano

R Romano

G Bellini

I Manzo

A Furiano

A Rizzo

R Imperatore

F A Iannotti

E DAniello

F Piscitelli

F Sca Rossi

L Cristino

V Di Marzo

V de Novellis

S Maione

Affiliations

Soon will be listed here.

Abstract

The endogenous fatty acid amide palmitoylethanolamide (PEA) has been shown to exert anti-inflammatory actions mainly through inhibition of the release of pro-inflammatory molecules from mast cells, monocytes and macrophages. Indirect activation of the endocannabinoid (eCB) system is among the several mechanisms of action that have been proposed to underlie the different effects of PEA in vivo. In this study, we used cultured rat microglia and human macrophages to evaluate whether PEA affects eCB signaling. PEA was found to increase CB2 mRNA and protein expression through peroxisome proliferator-activated receptor-α (PPAR-α) activation. This novel gene regulation mechanism was demonstrated through: (i) pharmacological PPAR-α manipulation, (ii) PPAR-α mRNA silencing, (iii) chromatin immunoprecipitation. Moreover, exposure to PEA induced morphological changes associated with a reactive microglial phenotype, including increased phagocytosis and migratory activity. Our findings suggest indirect regulation of microglial CB2R expression as a new possible mechanism underlying the effects of PEA. PEA can be explored as a useful tool for preventing/treating the symptoms associated with neuroinflammation in CNS disorders.

Citing Articles

The Endocannabinoid System: Implications in Gastrointestinal Physiology and Pathology.

Aloisio Caruso E, De Nunzio V, Tutino V, Notarnicola M Int J Mol Sci. 2025; 26(3).

PMID: 39941074 PMC: 11818434. DOI: 10.3390/ijms26031306.

A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review.

Varrassi G, Rekatsina M, Leoni M, Cascella M, Finco G, Sardo S Pain Ther. 2024; 14(1):81-101.

PMID: 39630391 PMC: 11751209. DOI: 10.1007/s40122-024-00685-4.

Novel fluorinated cannabinoid analogs modulate cytokine expression in human C20 microglial cells.

Davis R, Grotjahn S, Koenig B, Buck D, Weaver 3rd J Pharmacol Rep. 2024; 77(1):295-301.

PMID: 39612133 DOI: 10.1007/s43440-024-00680-8.

Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy.

Didangelos T, Karlafti E, Kotzakioulafi E, Giannoulaki P, Kontoninas Z, Kontana A Nutrients. 2024; 16(18).

PMID: 39339645 PMC: 11434759. DOI: 10.3390/nu16183045.

Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis.

Kumar A, Tatarian J, Shakhnovich V, Chevalier R, Sudman M, Lovell D Metabolites. 2024; 14(9).

PMID: 39330506 PMC: 11434325. DOI: 10.3390/metabo14090499.

References

Skaper S, Facci L, Giusti P . Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol. 2013; 48(2):340-52. DOI: 10.1007/s12035-013-8487-6. View

Fung S, Cherry A, Xu C, Stella N . Alkylindole-sensitive receptors modulate microglial cell migration and proliferation. Glia. 2015; 63(10):1797-808. PMC: 4418235. DOI: 10.1002/glia.22845. View

Iannotti F, Di Marzo V, Petrosino S . Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res. 2016; 62:107-28. DOI: 10.1016/j.plipres.2016.02.002. View

Calignano A, La Rana G, Piomelli D . A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Prog Brain Res. 2000; 129:471-82. DOI: 10.1016/s0079-6123(00)29034-1. View

Kettenmann H, Hanisch U, Noda M, Verkhratsky A . Physiology of microglia. Physiol Rev. 2011; 91(2):461-553. DOI: 10.1152/physrev.00011.2010. View

Guida F, Luongo L, Aviello G, Palazzo E, De Chiaro M, Gatta L . Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection. Mol Pain. 2012; 8:60. PMC: 3522567. DOI: 10.1186/1744-8069-8-60. View

Stella N . Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010; 58(9):1017-30. PMC: 2919281. DOI: 10.1002/glia.20983. View

Liu Q, Pan C, Hishimoto A, Li C, Xi Z, Llorente-Berzal A . Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav. 2009; 8(5):519-30. PMC: 3389515. DOI: 10.1111/j.1601-183X.2009.00498.x. View

Racz I, Nadal X, Alferink J, Banos J, Rehnelt J, Martin M . Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci. 2008; 28(46):12125-35. PMC: 3844839. DOI: 10.1523/JNEUROSCI.3400-08.2008. View

10.

Luongo L, Petrelli R, Gatta L, Giordano C, Guida F, Vita P . 5'-Chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A(1) receptor agonist, alleviates neuropathic pain in mice through functional glial and microglial changes without affecting motor or cardiovascular functions. Molecules. 2012; 17(12):13712-26. PMC: 6268894. DOI: 10.3390/molecules171213712. View

11.

Milligan E, Watkins L . Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2008; 10(1):23-36. PMC: 2752436. DOI: 10.1038/nrn2533. View

12.

Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M . Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 2001; 358(Pt 1):249-55. PMC: 1222054. DOI: 10.1042/0264-6021:3580249. View

13.

Loverme J, La Rana G, Russo R, Calignano A, Piomelli D . The search for the palmitoylethanolamide receptor. Life Sci. 2005; 77(14):1685-98. DOI: 10.1016/j.lfs.2005.05.012. View

14.

Koch M, Kreutz S, Bottger C, Benz A, Maronde E, Ghadban C . Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α. Neurotox Res. 2010; 19(2):330-40. DOI: 10.1007/s12640-010-9166-2. View

15.

Clark A, Wodarski R, Guida F, Sasso O, Malcangio M . Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor. Glia. 2010; 58(14):1710-26. DOI: 10.1002/glia.21042. View

16.

Scarampella F, Abramo F, Noli C . Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet Dermatol. 2001; 12(1):29-39. DOI: 10.1046/j.1365-3164.2001.00214.x. View

17.

Rinaldi B, Guida F, Furiano A, Donniacuo M, Luongo L, Gritti G . Effect of Prolonged Moderate Exercise on the Changes of Nonneuronal Cells in Early Myocardial Infarction. Neural Plast. 2015; 2015:265967. PMC: 4526216. DOI: 10.1155/2015/265967. View

18.

Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G . Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003; 23(4):1398-405. PMC: 6742252. View

19.

Mackie K, Stella N . Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006; 8(2):E298-306. PMC: 3231556. DOI: 10.1007/BF02854900. View

20.

Di Cesare Mannelli L, DAgostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C . Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm. 2013; 2013:328797. PMC: 3596927. DOI: 10.1155/2013/328797. View